Heron Therapeutics (HRTX) Upgraded by BidaskClub to Buy

BidaskClub upgraded shares of Heron Therapeutics (NASDAQ:HRTX) from a hold rating to a buy rating in a research note released on Saturday.

Other analysts have also issued research reports about the stock. Cantor Fitzgerald set a $40.00 price target on shares of Heron Therapeutics and gave the stock a buy rating in a research report on Thursday, May 10th. Needham & Company LLC restated a buy rating and issued a $30.00 target price (up previously from $28.00) on shares of Heron Therapeutics in a research report on Thursday, March 1st. ValuEngine upgraded shares of Heron Therapeutics from a sell rating to a hold rating in a research report on Tuesday, March 13th. Oppenheimer set a $34.00 target price on shares of Heron Therapeutics and gave the company a buy rating in a research report on Monday, March 19th. Finally, Noble Financial restated a buy rating on shares of Heron Therapeutics in a research report on Wednesday, March 21st. One investment analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company. The company has an average rating of Buy and an average price target of $36.54.

Heron Therapeutics opened at $32.65 on Friday, according to Marketbeat Ratings. Heron Therapeutics has a 1 year low of $12.70 and a 1 year high of $34.00.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Thursday, May 10th. The biotechnology company reported ($0.81) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.87) by $0.06. The business had revenue of $11.60 million for the quarter, compared to analyst estimates of $11.10 million. Heron Therapeutics had a negative net margin of 515.27% and a negative return on equity of 239.94%. The business’s quarterly revenue was up 222.2% compared to the same quarter last year. research analysts forecast that Heron Therapeutics will post -2.4 earnings per share for the current year.

In other news, VP Kimberly Manhard sold 18,000 shares of the firm’s stock in a transaction on Monday, March 19th. The shares were sold at an average price of $30.00, for a total transaction of $540,000.00. Following the completion of the transaction, the vice president now owns 18,000 shares of the company’s stock, valued at $540,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Barry D. Quart sold 100,000 shares of the firm’s stock in a transaction on Wednesday, March 14th. The shares were sold at an average price of $24.75, for a total transaction of $2,475,000.00. Following the transaction, the chief executive officer now directly owns 167,993 shares of the company’s stock, valued at approximately $4,157,826.75. The disclosure for this sale can be found here. Insiders sold 218,000 shares of company stock worth $5,990,000 in the last 90 days. Company insiders own 19.93% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in HRTX. Schwab Charles Investment Management Inc. raised its stake in shares of Heron Therapeutics by 50.7% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 242,934 shares of the biotechnology company’s stock valued at $4,398,000 after acquiring an additional 81,735 shares during the last quarter. Fox Run Management L.L.C. raised its stake in shares of Heron Therapeutics by 27.5% during the fourth quarter. Fox Run Management L.L.C. now owns 22,050 shares of the biotechnology company’s stock valued at $399,000 after acquiring an additional 4,750 shares during the last quarter. Fisher Asset Management LLC raised its stake in Heron Therapeutics by 20.6% during the fourth quarter. Fisher Asset Management LLC now owns 121,069 shares of the biotechnology company’s stock worth $2,191,000 after buying an additional 20,705 shares during the last quarter. Claraphi Advisory Network LLC bought a new position in Heron Therapeutics during the fourth quarter worth $335,000. Finally, Deltec Asset Management LLC bought a new position in Heron Therapeutics during the fourth quarter worth $2,118,000. 96.35% of the stock is owned by hedge funds and other institutional investors.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply